NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alpha Tau Medical Ltd. (DRTS) Stock Analysis

Alpha Tau Medical Ltd. (DRTS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DRTS

$13.48

+$0.39 (+2.98%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DRTS with… →

DRTS Key Statistics

As of Oct 21, 2026
Trading
Open
$13.44
Previous Close
$13.09
Day's Range
13.30–13.84
52-Week Range
3.43–15.79
Volume
498.76K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.22
Valuation
Market Cap
$1.25B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.04
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
92.48M
1-Year Return
+220.95%
Dividend and dates
Earnings Date
November 19, 2026estimated
Avg Volume
549.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DRTS closed at $13.48, +220.95% over 1 year.

Alpha Tau Medical Ltd. (DRTS) has a market capitalization of $1.25B.

In fiscal 2025, DRTS reported revenue of $0.00.

DRTS Stock Return by Calendar Year

Alpha Tau Medical Ltd. (DRTS) return since Mar 2021: what $10,000 became

1 year
$10,000 $32,095
+220.95%
5 years
$10,000 $13,602
+36.02%
Since Mar 2021
$10,000 $13,347
+33.47%

If you had invested $10,000 in Alpha Tau Medical Ltd. (DRTS) at the close on March 8, 2021, the earliest close on record here, it would have been worth $13,347 at the close on October 21, 2026: +33.47% in total, +5.27% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+172.32%
2025+59.68%
2024+2.99%
2023−5.35%
2022−67.62%
2021 (partial year)−2.77%

As of October 21, 2026.

DRTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$42.63M—
2024$0.00−$31.75M—
2023$0.00−$29.16M—
2022$0.00−$33.76M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$42.29M−$42.63M—
2024$0.00—−$36.04M−$31.75M—
2023$0.00—−$35.68M−$29.16M—
2022$0.00—−$32.14M−$33.76M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Alpha Tau Medical Ltd. (DRTS) at $1.25B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 121.

The most recent close on file for DRTS is $13.48, dated October 21, 2026. That is +$0.39 (+2.98%) against the previous close. The 52-week range on file runs from $3.43 to $15.79. The latest close sits 293% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $42.63M. Trailing earnings per share are −1.04.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +220.95%. Measured over 5 years, that is +6.35% a year compounded. Beta against the wider market is reported at 1.22. Daily returns over the trailing 5 years annualize to a volatility of 80.51%.

Growth & Income

No dividend is on file for DRTS.

The strongest complete calendar year on file is 2025 at +59.68%; the weakest is 2022 at −67.62%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +172.32% year to date.

Peer Comparison

Alpha Tau Medical Ltd. (DRTS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alpha Tau Medical Ltd. DRTS $1.25B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alpha Tau Medical Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Visit website →